Skip to content

Company · founded 1994

Indivior (United States)

Chesterfield, United States · indivior.com

Manage this page

Citations, last 5 years: 464
Works, last 5 years: 75
h-index: 47
Scientists listed: 11
Grants since 2016: 5

Grants received

2019–2021 · cooperative agreement · UG3

Clinical Evaluation of C4X3256, a Non-Opioid, Highly-Selective Orexin-1 Receptor Antagonist for the Treatment of Opioid Use Disorder

Christian Arthur Heidbreder · Indivior (United States) · funded by National Institutes of Health

$3MSleep and Wakefulness Research

2019–2023 · cooperative agreement · UG3

Clinical Evaluation of C4X3256, a Non-Opioid, Highly-Selective Orexin-1 Receptor Antagonist for the Treatment of Opioid Use Disorder

Christian Arthur Heidbreder · Indivior (United States) · funded by National Institutes of Health

$2.8MSleep and Wakefulness Research

2019–2026 · cooperative agreement · UH3

Clinical Evaluation of C4X3256, a Non-Opioid, Highly-Selective Orexin-1 Receptor Antagonist for the Treatment of Opioid Use Disorder

Christian Arthur Heidbreder · Indivior (United States) · funded by National Institutes of Health

$2.4MSleep and Wakefulness Research

2019–2026 · cooperative agreement · UH3

Clinical Evaluation of C4X3256, a Non-Opioid, Highly-Selective Orexin-1 Receptor Antagonist for the Treatment of Opioid Use Disorder

Christian Arthur Heidbreder · Indivior (United States) · funded by National Institutes of Health

$287.2kSleep and Wakefulness Research

2019–2026 · cooperative agreement · UH3

Clinical Evaluation of C4X3256, a Non-Opioid, Highly-Selective Orexin-1 Receptor Antagonist for the Treatment of Opioid Use Disorder

Christian Arthur Heidbreder · Indivior (United States) · funded by National Institutes of Health

$38.4k